Fosmanogepix

Fosmanogepix (APX001) is an orally bioavailable prodrug that is rapidly converted in vivo to its active form, APX001A, a broad-spectrum antifungal targeting the conserved Gwt1 enzyme. It demonstrates promising in vitro and in vivo efficacy against invasive fungal infections like candidiasis and aspergillosis, making it a valuable research tool for antifungal development.